Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD
Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.
- Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.
- As a reminder, the Company is currently subject to receivership proceedings and is actively looking for buyers to acquire the Company’s business.
- The deadline for submission of offers has been set to November 20, 2023, at 12:00 p.m. (noon) CET.
- Pixium will continue to regularly inform the market on the progress of the procedure and, more generally, of Pixium Vision’s financial situation.